Antonios Vlahos, Dimitrios Rallis, Alexandra Lianou, Maria Baltogianni, Niki Dermitzaki, Eleni Maragoudaki, Eleni Papastergiou, Christos Tzallas, Sophia Tsabouri, Alexandros Makis, Ekaterini Siomou, Haralambos Milionis, Vasileios Giapros
OBJECTIVE: Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9), a modulator of low-density lipoprotein (LDL) cholesterol metabolism, has been reported to be a promising biomarker for evaluating lipoprotein metabolism; however, evidence in infants is limited. In the current study, we sought to investigate potential differences in serum PCSK9 levels between infants with deviant birth weight and controls. METHODS: We enrolled 82 infants, classified into 33 small (SGA), 32 appropriate (AGA), and 17 large for gestation (LGA) infants...
December 2023: Journal of Maternal-fetal & Neonatal Medicine